1,092 results

#112164-AAV1

Ready-to-use AAV1 particles produced from pAAV.hSyn-FLEX.iGABASnFR.F102G (#112164). In addition to the viral particles, you will also receive purified pAAV.hSyn-FLEX.iGABASnFR.F102G plasmid DNA. Synapsin-driven, Cre-dependent iGABASnFR.F102G GABA sensor. These AAV preparations are suitable purity for injection into animals.

Loren Looger

Marvin et al Nat Methods. 2019 Aug;16(8):763-770. doi

Jan. 3, 2019

Academic Institutions and Nonprofits only

#55641-AAV1

Ready-to-use AAV1 particles produced from pAAV-Ef1a-fDIO EYFP (#55641). In addition to the viral particles, you will also receive purified pAAV-Ef1a-fDIO EYFP plasmid DNA. EF1a-driven, Flp-dependent expression of EYFP. These AAV preparations are suitable purity for injection into animals.

Karl Deisseroth

Fenno et al Nat Methods. 2014 Jul;11(7):763-72. doi:

Aug. 28, 2020

Academic Institutions and Nonprofits only

#105532-AAV8

Ready-to-use AAV8 particles produced from pAAV.CMV.ffLuciferase.SV40 (#105532). In addition to the viral particles, you will also receive purified pAAV.CMV.ffLuciferase.SV40 plasmid DNA. CMV-driven ffLuciferase control. These AAV preparations are suitable purity for injection into animals.

James M. Wilson

June 29, 2018

Academic Institutions and Nonprofits only

#119744-AAV5

Ready-to-use AAV5 particles produced from AAV CAMKII PSAM4 GlyR IRES EGFP (#119744). In addition to the viral particles, you will also receive purified AAV CAMKII PSAM4 GlyR IRES EGFP plasmid DNA. CamKII-driven expression of PSAM4 GlyR IRES EGFP for neuronal silencing. These AAV preparations are suitable purity for injection into animals.

Scott Sternson

Magnus et al Science. 2019 Mar 14. pii: science.aav52

Aug. 28, 2020

Academic Institutions and Nonprofits only

#50465-AAV2.T

Ready-to-use AAV2 trial size particles produced from pAAV-hSyn-EGFP (#50465). In addition to the viral particles, you will also receive purified pAAV-hSyn-EGFP plasmid DNA. hSyn-driven EGFP expression. These AAV preparations are suitable purity for injection into animals.

Bryan Roth

July 31, 2019

Academic Institutions and Nonprofits only

#213815-AAV1

Ready-to-use AAV1 particles produced from pAAV_BiSSTe10_ChR2_mCherry (#213815). In addition to the viral particles, you will also receive purified pAAV_BiSSTe10_ChR2_mCherry plasmid DNA. Expression of mCherry-tagged channelrhodopsin-2 under the control of the SST interneuron-targeting enhancer E10. These AAV preparations are suitable purity for injection into animals.

Gordon Fishell

Furlanis et al Neuron. 2025 May 21;113(10):1525-1547.e1

Sept. 23, 2025

Academic Institutions and Nonprofits only

#154868-AAVrg

Ready-to-use AAV Retrograde particles produced from pAAV-hSyn-fDIO-hM3D(Gq)-mCherry-WPREpA (#154868). In addition to the viral particles, you will also receive purified pAAV-hSyn-fDIO-hM3D(Gq)-mCherry-WPREpA plasmid DNA. Syn-driven, Flp-dependent hM3D(Gq) receptor with an mCherry reporter for CNO-induced neuronal activation. These AAV were produced with a retrograde serotype, which permits retrograde access to projection neurons. These AAV preparations are suitable purity for injection into animals.

Ulrik Gether

Oct. 8, 2020

Academic Institutions and Nonprofits only

#100061-AAV9

Ready-to-use AAV9 particles produced from pAAV-Ef1a-DIO C1V1 (t/t)-TS-mCherry (PV2670) (#100061). In addition to the viral particles, you will also receive purified pAAV-Ef1a-DIO C1V1 (t/t)-TS-mCherry (PV2670) plasmid DNA. EFIa-driven, Cre-dependent, C1V1 (t/t) fused to mCherry for optogenetic activation. These AAV preparations are suitable purity for injection into animals.

Karl Deisseroth

April 6, 2018

Academic Institutions and Nonprofits only

#51082-AAV1

Ready-to-use AAV1 particles produced from AAV-EF1a-DIO-GCaMP6s-P2A-nls-dTomato (#51082). In addition to the viral particles, you will also receive purified AAV-EF1a-DIO-GCaMP6s-P2A-nls-dTomato plasmid DNA. GCaMP6s calcium sensor and bicistronic, physically separate nuclear localized dTomato expression under the EF1a promoter. These AAV preparations are suitable purity for injection into animals.

Jonathan Ting

Sept. 19, 2017

Academic Institutions and Nonprofits only

#121675-AAV5

Ready-to-use AAV5 particles produced from pAAV-EF1a-fDIO-Cre (#121675). In addition to the viral particles, you will also receive purified pAAV-EF1a-fDIO-Cre plasmid DNA. EF1a-driven, Flp recombinase dependent expression of Cre recombinase. These AAV preparations are suitable purity for injection into animals.

Esteban Engel, Alexander Nectow

Schneeberger et al Cell. 2019 Jun 24. pii: S0092-8674(19)30

Sept. 27, 2024

Academic Institutions and Nonprofits only

#92379-LV

Ready-to-use Lentiviral Prep particles produced from Human CRISPRa sgRNA library Calabrese in backbone XPR_502 (P65 HSF), Set A (#92379). In addition to the viral particles, you will also receive purified Human CRISPRa sgRNA library Calabrese in backbone XPR_502 (P65 HSF), Set A plasmid DNA. Ready-to-use lentiviral pooled library for CRISPR activation screening in human cells. Contains 56,762 sgRNAs, targeting 18,885 genes. Concentrated lentiviral particles carrying set A of the Calabrese human CRISPRa sgRNA activation library in backbone XPR_502 (P65 HSF) .

John Doench, David Root

Sanson et al Nat Commun. 2018 Dec 21;9(1):5416. doi:

Aug. 3, 2017

Academic Institutions and Nonprofits only

#100842-AAV5

Ready-to-use AAV5 particles produced from pAAV.CAG.Flex.GCaMP6s.WPRE.SV40 (#100842). In addition to the viral particles, you will also receive purified pAAV.CAG.Flex.GCaMP6s.WPRE.SV40 plasmid DNA. CAG-driven, Cre-dependent GCaMP6s calcium sensor. These AAV preparations are suitable purity for injection into animals.

Douglas Kim, GENIE Project

Chen et al Nature. 2013 Jul 18;499(7458):295-300. d

May 11, 2018

Academic Institutions and Nonprofits only

#55650-AAVrg

Ready-to-use AAV Retrograde particles produced from pAAV-hSyn Con/Fon EYFP (#55650). In addition to the viral particles, you will also receive purified pAAV-hSyn Con/Fon EYFP plasmid DNA. Synapsin driven, Cre and Flp-dependent EYFP expression. These AAV were produced with a retrograde serotype, which permits retrograde access to projection neurons. These AAV preparations are suitable purity for injection into animals.

Karl Deisseroth

Fenno et al Nat Methods. 2014 Jul;11(7):763-72. doi:

Sept. 8, 2020

Academic Institutions and Nonprofits only

#26968-AAV9

Ready-to-use AAV9 particles produced from pAAV-Ef1a-DIO ChETA-EYFP (#26968). In addition to the viral particles, you will also receive purified pAAV-Ef1a-DIO ChETA-EYFP plasmid DNA. EF1a-driven, Cre-dependent, ChETA fused to EYFP for optogenetic activation. These AAV preparations are suitable purity for injection into animals.

Karl Deisseroth

Gunaydin et al Nat Neurosci. 2010 Mar;13(3):387-92. doi

March 30, 2018

Academic Institutions and Nonprofits only

#105537-AAV5

Ready-to-use AAV5 particles produced from pENN.AAV.CMVs.Pl.Cre.rBG (#105537). In addition to the viral particles, you will also receive purified pENN.AAV.CMVs.Pl.Cre.rBG plasmid DNA. CMV-driven Cre. These AAV preparations are suitable purity for injection into animals.

James M. Wilson

Feb. 7, 2025

Academic Institutions and Nonprofits only

#114470-AAVrg

Ready-to-use AAV Retrograde particles produced from pAAV-Ef1a-mCherry (#114470). In addition to the viral particles, you will also receive purified pAAV-Ef1a-mCherry plasmid DNA. EF1a-driven mCherry expression. These AAV were produced with a retrograde serotype, which permits retrograde access to projection neurons. These AAV preparations are suitable purity for injection into animals.

Karl Deisseroth

Sept. 15, 2021

Academic Institutions and Nonprofits only

#26966-AAV1

Ready-to-use AAV1 particles produced from pAAV-Ef1a-DIO eNpHR 3.0-EYFP (#26966). In addition to the viral particles, you will also receive purified pAAV-Ef1a-DIO eNpHR 3.0-EYFP plasmid DNA. EF1a-driven, cre-dependent eNpHR 3.0-EYFP for optogenetic inhibition. These AAV preparations are suitable purity for injection into animals.

Karl Deisseroth

Gradinaru et al Cell. 2010 Apr 2. 141(1):154-65.

Feb. 14, 2018

Academic Institutions and Nonprofits only

#50465-AAV8.T

Ready-to-use AAV8 trial size particles produced from pAAV-hSyn-EGFP (#50465). In addition to the viral particles, you will also receive purified pAAV-hSyn-EGFP plasmid DNA. hSyn-driven EGFP expression. These AAV preparations are suitable purity for injection into animals.

Bryan Roth

May 29, 2019

Academic Institutions and Nonprofits only

#51085-AAVrg

Ready-to-use AAV Retrograde particles produced from AAV-hSyn1-GCaMP6f-P2A-nls-dTomato (#51085). In addition to the viral particles, you will also receive purified AAV-hSyn1-GCaMP6f-P2A-nls-dTomato plasmid DNA. GCaMP6f calcium sensor and bicistronic, physically separate nuclear localized dTomato expression under a human synapsin1 promoter. These AAV were produced with a retrograde serotype, which permits retrograde access to projection neurons. These AAV preparations are suitable purity for injection into animals.

Jonathan Ting

May 10, 2017

Academic Institutions and Nonprofits only

#112005-AAV9

Ready-to-use AAV9 particles produced from pAAV-hSynapsin1-axon-GCaMP6s-P2A-mRuby3 (#112005). In addition to the viral particles, you will also receive purified pAAV-hSynapsin1-axon-GCaMP6s-P2A-mRuby3 plasmid DNA. Synapsin-driven, axon-targeted GCaMP6s calcium sensor and mRuby3 expression. The mRuby3 will be a separate protein (not a fusion protein). These AAV preparations are suitable purity for injection into animals.

Lin Tian

Broussard et al Nat Neurosci. 2018 Sep;21(9):1272-1280.

April 24, 2019

Academic Institutions and Nonprofits only